Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference.
SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference, which will be held virtually March 15 to 17.
32nd Annual Oppenheimer Healthcare Conference
Date: Tuesday, March 15
Time: 2:40 p.m. ET
More information about the conference can be found here.
About Primmune Therapeutics
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapy TherAjuvants™ for the treatment of cancers and viral diseases. For more information, please visit https://www.primmunerx.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005202/en/
Source: Primmune Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20220310005202/en
